文献速递儿科与产科急症重症综合管理与镇静镇痛

国家新生儿重症监护快速基因组测序

National Rapid Genome Sequencing in Neonatal Intensive Care.
PubMed 文献 · JAMA Netw Open · 2024-02-05
一句话结论以色列全国多中心前瞻性队列显示,危重新生儿快速三联基因组测序7(3)天出报告,50%(65/130)检出致病性变异,22%的受访者因此改变医疗管理。

该研究为2021年10月至2022年12月在以色列开展的前瞻性、公共卫生保健为基础的多中心队列研究,覆盖全部以色列医学遗传学研究所(n=18)和新生儿重症监护病房(NICU,n=25),纳入疑似遗传病因的危重新生儿130例(男70例[54%],女60例[46%]),入组平均(SD)年龄12(13)天。快速报告平均(SD)周转时间7(3)天;诊断效能为致病性变异50%(65/130)、疑似致病性VUS 11%(14/130)、1个新基因候选(1%)。临床效用问卷应答率82%(107/130),其中基因组检测使24例(22%)的医疗管理发生改变;6/65例确诊婴儿(9%)获得即时精准医疗,另2例(3%)接受姑息治疗,2例(3%)转至护理院。作者认为,在公共卫生保健环境下对危重新生儿开展rtGS可行且具有诊断获益,是将其纳入常规照护的先决条件,并可能有助于其他公共卫生系统设计类似研究。

要点

  • 危重疑似遗传病新生儿行快速三联基因组测序,快速报告平均(SD)7(3)天出结果,满足NICU急性期决策时间需求。
  • 130例中致病性变异诊断效能50%(65/130),疑似致病性VUS 11%(14/130),另发现1个新基因候选(1%)。
  • 临床效用问卷应答率82%(107/130),其中24例(22%)因基因组检测改变医疗管理。
  • 65例确诊婴儿中6例(9%)获得即时精准医疗,2例(3%)接受姑息治疗,2例(3%)转至护理院。
  • 致病性变异包括12例染色体病、52例单基因病和1例单亲二体。

适用人群与场景

  • 以色列全国25个NICU中疑似遗传病因的危重新生儿,入组平均(SD)年龄12(13)天。
  • 研究于2021年10月至2022年12月开展,由以色列卫生部社区遗传学部门与全部18个以色列医学遗传学研究所和25个NICU参与。

诊断标准与关键阈值

  • 对疑似遗传病因的危重新生儿提供快速三联基因组测序(rtGS)。
  • 报告致病性、可能致病性及高度怀疑的VUS变异。

处置流程与药物剂量

  • 所有测序、分析和数据解读在Tel-Aviv Sourasky医疗中心中央基因组学中心完成。
  • 快速结果预期在10天内出具。
  • 在60天内出具二次分析报告,主要关注快速结果阴性且存在可操作次要发现者。

研究设计与关键结果

  • 研究类型:前瞻性、公共卫生保健为基础的多中心队列研究;纳入130例危重新生儿(男70例[54%],女60例[46%]),来自以色列18个医学遗传学研究所和25个NICU。
  • 快速报告平均(SD)周转时间7(3)天。
  • 诊断效能:致病性变异50%(65/130),疑似致病性VUS 11%(14/130),1个新基因候选(1%)。
  • 致病性变异构成:12例染色体病、52例单基因病、1例单亲二体。
  • 临床效用问卷应答率82%(107/130);应答者中24例(22%)因基因组检测改变医疗管理。
  • 65例确诊婴儿中,6例(9%)获得即时精准医疗,2例(3%)接受姑息治疗,2例(3%)转至护理院。

证据类型、等级与局限

  • 证据类型:前瞻性、公共卫生保健为基础的多中心队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,在公共卫生保健环境下对危重新生儿开展rtGS可行且具有诊断获益。
  • 作者认为,本研究是将rtGS纳入危重新生儿常规照护的先决条件,并可能有助于其他公共卫生系统设计类似研究。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: National implementation of rapid trio genome sequencing (rtGS) in a clinical acute setting is essential to ensure advanced and equitable care for ill neonates.

OBJECTIVE: To evaluate the feasibility, diagnostic efficacy, and clinical utility of rtGS in neonatal intensive care units (NICUs) throughout Israel.

DESIGN, SETTING, AND PARTICIPANTS: This prospective, public health care-based, multicenter cohort study was conducted from October 2021 to December 2022 with the Community Genetics Department of the Israeli Ministry of Health and all Israeli medical genetics institutes (n = 18) and NICUs (n = 25). Critically ill neonates suspected of having a genetic etiology were offered rtGS. All sequencing, analysis, and interpretation of data were performed in a central genomics center at Tel-Aviv Sourasky Medical Center. Rapid results were expected within 10 days. A secondary analysis report, issued within 60 days, focused mainly on cases with negative rapid results and actionable secondary findings. Pathogenic, likely pathogenic, and highly suspected variants of unknown significance (VUS) were reported.

MAIN OUTCOMES AND MEASURES: Diagnostic rate, including highly suspected disease-causing VUS, and turnaround time for rapid results. Clinical utility was assessed via questionnaires circulated to treating neonatologists.

RESULTS: A total of 130 neonates across Israel (70 [54%] male; 60 [46%] female) met inclusion criteria and were recruited. Mean (SD) age at enrollment was 12 (13) days. Mean (SD) turnaround time for rapid report was 7 (3) days. Diagnostic efficacy was 50% (65 of 130) for disease-causing variants, 11% (14 of 130) for VUS suspected to be causative, and 1 novel gene candidate (1%). Disease-causing variants included 12 chromosomal and 52 monogenic disorders as well as 1 neonate with uniparental disomy. Overall, the response rate for clinical utility questionnaires was 82% (107 of 130). Among respondents, genomic testing led to a change in medical management for 24 neonates (22%). Results led to immediate precision medicine for 6 of 65 diagnosed infants (9%), an additional 2 (3%) received palliative care, and 2 (3%) were transferred to nursing homes.

CONCLUSIONS AND RELEVANCE: In this national cohort study, rtGS in critically ill neonates was feasible and diagnostically beneficial in a public health care setting. This study is a prerequisite for implementation of rtGS for ill neonates into routine care and may aid in design of similar studies in other public health care systems.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Marom D, Mory A, Reytan-Miron S, et al. National Rapid Genome Sequencing in Neonatal Intensive Care. JAMA Netw Open. 2024. PMID: 38386321. doi:10.1001/jamanetworkopen.2024.0146

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。